NEW ROCHELLE, N.Y., Feb. 2 /PRNewswire/ -- Since the cloning of Dolly the Sheep over a decade ago, somatic cell nuclear transfer (SCNT) has been considered a promising way to generate human, patient-specific stem cells for therapeutic applications. The shortage of human donor eggs has led to efforts to substitute animal oocytes. However, a new study published online ahead of print in the Volume 11, Number 2, 2009 issue of Cloning and Stem Cells, a peer-reviewed journal published by Mary Ann Liebert, Inc., demonstrates that animal oocytes lack the capacity to fully reprogram adult human cells. The paper is available free online at www.liebertpub.com/clo
Robert Lanza, M.D. and colleagues from Advanced Cell Technology (Worcester, MA),
The ability to reprogram human cells using oocytes would enable the production of patient-specific stem cells that could then be differentiated to become any type of somatic cell and used for cell or tissue repair or placement therapy. This extensive reprogramming requires that the oocyte turn on, or up-regulate a large number of genes in the donor nucleus.
Although previous reports have documented the formation of cloned embryos using both human and animal eggs, to date, there have been no data indicating to what extent the donor human DNA was reprogrammed. Lanza et al. show for the first time that human oocytes have the capacity to change these patterns of gene expression, and that interspecies (human-to-animal) cloning does not produce the same results. Although the human-bovine and human-rabbit clones looked similar to the human-human embryos, the human-animal hybrids did not exhibit the changes in gene expression seen in the human-human clones and normal embryos. Specifically, they did not achieve up-regulation of critical pluripotency-associated genes needed for stem cell production.
"This very important paper suggests that livestock oocytes are extremely unlikely to be suitable as recipients for use in human nuclear transfer. This is very disappointing because it would mean that production of patient-specific stem cells by this means would be impracticable,"
says Ian Wilmut, Ph.D., Editor-in-Chief of Cloning and Stem Cells and director of the Centre for Regenerative Medicine, in Edinburgh.
Cloning and Stem Cells is an authoritative peer-reviewed journal published quarterly in print and online that focuses on understanding developmental plasticity and defining the molecular mechanisms that regulate differentiation or dedifferentiation of nuclei and cells. Tables of contents and a free sample issue may be viewed online at www.liebertpub.com/clo
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Stem Cells and Development, and Tissue Engineering. Its biotechnology trade magazine, Genetic Engineering and Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT
Contact: Julia Chapman, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2147, email@example.com
Copyright©2009 PR Newswire.
All rights reserved